ReviewMolecular therapy. Oncology2025
Emerging roles of protein arginine methyltransferase in multiple myeloma.
Review in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Targeting PRMTs with small-molecule inhibitors: a comprehensive review.RSC medicinal chemistry · 2026Review
- Meeting report on FASEB protein arginine methylation: mechanism to therapeutics.The Journal of biological chemistry · 2026Article
- Protein Arginine Methyltransferases in γ-Globin Regulation and Sickle Cell Disease: Emerging Connections to Oxidative Stress.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) is a cancer of plasma cells characterized by the clonal expansion of abnormal plasma cells in the bone marrow. These malignant cells overcrowd the bone marrow, disrupt normal hematopoiesis, and produce excessive amounts of immunoglobulins, leading to severe clinical manifestations. Despite significant advancements in treatment, relapsed/refractory MM remains incurable. Protein arginine methylation, catalyzed by protein arginine methyltransferases (PRMTs), is a critical post-translational modification involved in regulating various cellular processes. Aberrant expression of PRMTs has been strongly linked to poor prognosis in many cancers, including MM. Among the PRMT family, PRMT1, PRMT4 (CARM1), and PRMT5 have emerged as potential therapeutic targets for MM. This review will first explore the expression patterns of PRMTs in MM and assess their association with disease prognosis. We will then provide a comprehensive overview of the functions of these PRMTs in MM pathology, discuss the development of PRMT inhibitors currently being evaluated in clinical trials, and offer insights into the potential of targeting PRMTs for MM treatment in clinical settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.